There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it.

In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade.

CHAPTERS:
00:00 — Introduction: The Blood Test Number Better Than Cholesterol
00:35 — What Is Lymphopenia and Why It Matters
01:50 — Immunosenescence: Why Your T Cells Decline After Age 20
02:30 — The Mortality Data: Three Studies on Lymphopenia
03:20 — Copenhagen Study: 63% Higher All-Cause Mortality
03:50 — Coronary Angiography Study: Hazard Ratio 1.97
04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells
05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer
06:00 — Four Hallmarks of Aging Hit By One Molecule
06:30 — ANKTIVA Explained: The IL-15 Super-Agonist
07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe
08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case
09:00 — The Skeptical Case: Why We Don't Know Yet
10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally
11:30 — Final Take and Closing

KEY TAKEAWAYS:

• Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studies
• IL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancer
• Resistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay young
• ANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatment
• IL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopenia
• Honest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this space

STUDIES & SOURCES MENTIONED:

• Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES)
• Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adults
• Bawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patients
• FDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancer

Watch the full video on YouTube: https://youtu.be/220KHIdFCwg

📖 Dr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/
📰 Substack newsletter: https://robertlufkinmd.substack.com
🌐 Website: https://robertlufkinmd.com

Enjoyed this episode? Reviews on Apple Podcasts are the #1 way to help the show grow. Tap here to leave one in 30 seconds: https://podcasts.apple.com/us/podcast/health-longevity-secrets/id1585563694

⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com
Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Web: https://www.robertlufkinmd.com
YouTube: https://www.youtube.com/robertlufkinmd
X: https://x.com/robertlufkinmd
Instagram: https://www.instagram.com/robertlufkinmd/
TikTok: https://www.tiktok.com/@robertlufkin
LinkedIn: https://www.linkedin.com/in/robertlufkinmd/